Lixte Biotechnology Stock Soars 49.5% on Private Placement

Lixte Biotechnology's stock surged by 49.5% in pre-market trading on July 4, 2025, marking a significant rise that has caught the attention of investors and analysts alike.

Lixte Biotechnology Holdings, Inc. recently announced a $5 million private placement to secure immediate liquidity and avoid potential delisting from the Nasdaq. This move is aimed at raising funds for general corporate purposes and working capital, which could help the company meet Nasdaq's compliance requirements.

The private placement includes the issuance of Common Stock, Series B Convertible Preferred Stock, and Common Warrants, priced at market under Nasdaq rules. The transaction is expected to close on July 2, 2025, and is anticipated to boost the company’s stockholders’ equity above $2.5 million, pending Nasdaq compliance determination.

Lixte Biotechnology is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company's lead compound, LB-100, is a PP2A inhibitor that has shown potential to enhance chemotherapies and immunotherapies, making it a key player in the field of cancer biology known as activation lethality.